Introduction: Prodromal constipation (PC) at Parkinson's disease (PD) onset may mark a distinct neurodegen-erative trajectory; accordingly, presenting phenotype, biochemical signature, and progression of PD patients with PC (PD + PC) might differ from those without (PDwoPC). We compared the clinical-biochemical profile of de novo PD patients with and without PC, and the respective mid-term progression, to establish the grouping effect of PC. Methods: Motor and non-motor scores were collected at diagnosis in n = 57 PD + PC patients and n = 73 PDwoPC. Paired CSF biomarkers (alpha-synuclein, amyloid and tau peptides, lactate, CSF/serum albumin ratio or AR) were assessed into a smaller sample and n = 46 controls. Clinical progression was estimated as Hoehn and Yahr stage (HY) and levodopa equivalent daily dose (LEDD) change 2.06 +/- 1.35 years after diagnosis. Results: At onset, PD + PC patients had higher HY and MDS-UPDRS-part III scores, and higher CSF AR. PDwoPC had higher Non-Motor Symptoms Scale domain-2 score, and lower CSF alpha-synuclein level. At follow-up, PD + PC had greater LEDD. Conclusions: PC identifies a group of de novo patients with more severe motor impairment, possible blood brain barrier disruption, and greater dopaminergic requirement at mid-term; conversely, de novo PDwoPC patients had prominent fatigue, and pronounced central synucleinopathy.
Grillo, P., Sancesario, G.m., Mascioli, D., Geusa, L., Zenuni, H., Giannella, E., et al. (2022). Constipation distinguishes different clinical-biochemical patterns in de novo Parkinson's disease. PARKINSONISM & RELATED DISORDERS, 102, 64-67 [10.1016/j.parkreldis.2022.08.001].
Constipation distinguishes different clinical-biochemical patterns in de novo Parkinson's disease
Della Morte, David;Mercuri, Nicola Biagio;Schirinzi, Tommaso
2022-09-01
Abstract
Introduction: Prodromal constipation (PC) at Parkinson's disease (PD) onset may mark a distinct neurodegen-erative trajectory; accordingly, presenting phenotype, biochemical signature, and progression of PD patients with PC (PD + PC) might differ from those without (PDwoPC). We compared the clinical-biochemical profile of de novo PD patients with and without PC, and the respective mid-term progression, to establish the grouping effect of PC. Methods: Motor and non-motor scores were collected at diagnosis in n = 57 PD + PC patients and n = 73 PDwoPC. Paired CSF biomarkers (alpha-synuclein, amyloid and tau peptides, lactate, CSF/serum albumin ratio or AR) were assessed into a smaller sample and n = 46 controls. Clinical progression was estimated as Hoehn and Yahr stage (HY) and levodopa equivalent daily dose (LEDD) change 2.06 +/- 1.35 years after diagnosis. Results: At onset, PD + PC patients had higher HY and MDS-UPDRS-part III scores, and higher CSF AR. PDwoPC had higher Non-Motor Symptoms Scale domain-2 score, and lower CSF alpha-synuclein level. At follow-up, PD + PC had greater LEDD. Conclusions: PC identifies a group of de novo patients with more severe motor impairment, possible blood brain barrier disruption, and greater dopaminergic requirement at mid-term; conversely, de novo PDwoPC patients had prominent fatigue, and pronounced central synucleinopathy.File | Dimensione | Formato | |
---|---|---|---|
Parkinson.pdf
solo utenti autorizzati
Tipologia:
Versione Editoriale (PDF)
Licenza:
Copyright dell'editore
Dimensione
335.23 kB
Formato
Adobe PDF
|
335.23 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.